HAND AND FOOT PEAK PRURITUS NRS EFFICACY RESULTS

SIGNIFICANT ITCH RELIEF IN ATOPIC DERMATITIS
PATIENTS AGED 12+ YEARS WITH UNCONTROLLED
MODERATE-TO-SEVERE HAND AND/OR FOOT INVOLVEMENT

Itch results demonstrated in a Phase 3 study of patients 12+ years of age^1-3

12+ YEARS

Itch reduction results at Week 16 (secondary endpoint)

Improvement after first dose at Week 2
(15% vs 3%)

Percentage of patients achieving ≥4-point
reductionin hand and foot Peak Pruritus NRS

Weeks

52%

≈4x as many
patients
(P<0.0001)

14%

DUPIXENT 200/300 mg Q2W (n=67) Placebo (n=66)

Definitive conclusions cannot be made for time points earlier than Week 16 as those data were not multiplicity-controlled
and P value was nominal.

Not an actual patient.

≈4x

As many patients

taking DUPIXENT achieved itch improvement at Week 16 vs placebo^1-3

taking DUPIXENT achieved itch
improvement at Week 16 vs placebo^1-3

Thinking about prescribing DUPIXENT?
Find the information you need to get started.